Sonnet BioTherapeutics Files 8-K

TL;DR

Sonnet BioTherapeutics filed an 8-K on Nov 18, 2025. Standard disclosure.

AI Summary

Sonnet BioTherapeutics Holdings, Inc. filed an 8-K on November 18, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as Chanticleer Holdings, Inc. and TULVINE SYSTEMS INC, is incorporated in Delaware and headquartered in Princeton, NJ.

Why It Matters

This filing provides an update on Sonnet BioTherapeutics' regulatory and financial disclosures, which is important for investors to stay informed about the company's official communications.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically contains standard disclosures and does not indicate any unusual or significant events.

Key Players & Entities

• Sonnet BioTherapeutics Holdings, Inc. (company) — Registrant
• November 18, 2025 (date) — Date of earliest event reported
• Chanticleer Holdings, Inc. (company) — Former company name
• TULVINE SYSTEMS INC (company) — Former company name
• Delaware (jurisdiction) — State of incorporation
• 001-35570 (identifier) — Commission File Number
• Princeton, NJ (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share SONN The Nasdaq Capital M

Filing Documents

• form8-k.htm (8-K) — 44KB
• ex99-1.htm (EX-99.1) — 20KB
• ex99-1_001.jpg (GRAPHIC) — 6KB
• 0001493152-25-024006.txt ( ) — 241KB
• sonn-20251118.xsd (EX-101.SCH) — 3KB
• sonn-20251118_lab.xml (EX-101.LAB) — 33KB
• sonn-20251118_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On November 18, 2025, Sonnet BioTherapeutics Holdings, Inc. (the "Company") issued a press release announcing the adjournment of its special meeting of stockholders (the "Special Meeting") to 9:00 a.m. Eastern Time on December 2, 2025, to allow additional time for stockholders to vote on its proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC, and the other proposals to be considered at the Special Meeting. The Company's stockholders of record as of October 20, 2025, the record date for the Special Meeting, will continue to be entitled to vote at the reconvened Special Meeting. Stockholders may attend the Special Meeting at the website address https://web.viewproxy.com/sonn/2025SM . A copy of the press release is attached hereto as Exhibit 99.1. The press release and the information set forth therein shall not be deemed to be filed for purposes of Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act, or the Exchange Act. Additional Information about the Proposed Business Combination Transaction and Where to Find It This Current Report on Form 8-K does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This Current Report on Form 8-K relates to a proposed business combination transaction. In connection with the proposed business combination transaction, HSI has filed a registration statement on Form S-4, containing a preliminary proxy statement for the Company's stockholders that will also constitute a preliminary prospectus of HSI, the securities of which are expected to be listed on Nasdaq upon consummation of the proposed business combination transaction. The Company mailed a definitive proxy statement/prospectus to the Company's

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sonnet BioTherapeutics Holdings, Inc. November 18, 2025 By: /s/ Raghu Rao Name: Raghu Rao Title: Interim Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR